UCB S.A., a biopharmaceutical company, focuses on various diseases in therapeutic areas of neurology and immunology in Belgium and internationally. The companys products include Cimzia for Crohns disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis; Vimpat for the treatment of partial-onset seizures; and Neupro for Parkinsons disease and restless legs syndrome. It also offers Keppra for epilepsy; Zyrtec and Xyzal for allergy; Metadate for attention deficit and hyperactivity disorders; Nootropil for the treatment of vertigo and events associated with ageing; and Xyrem for narcolepsy. In addition, the company provides Tussionex for relief of cough and upper respiratory symptoms associated with allergy or a cold; and Lortab for the relief from pain. The companys development stage products include brivaracetam as adjunctive therapy for epilepsy; tozadenant for Parkinsons disease; epratuzumab for systemic lupus erythematosus; romosozumab for osteoporosis; UCB4940 for psoriatic arthritis; UCB5857 and UCB7665 for immunological diseases; UCB4942 for drug resistant epilepsy; and dapirolizumab pegol for systemic lupus erythematosus. It has strategic alliances with the Weill Cornell Medical College (U.S.), Sanofi, and Dermira Inc., as well as collaboration and agreement with Neuropore Therapies Inc. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.
UCB/b - UCB S.A.
Is shortable: YesTrading hours:
|Market is closed||10:00 - 18:29||10:00 - 18:29||10:00 - 18:29||10:00 - 18:29||10:00 - 18:29||Market is closed|
|Long position||Short position|
|–3% ||-3% |
Temporary margin requirements due to upcoming corporate events: